Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

M.D. ANDERSON CANCER CENTER

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Personalized Treatment Selection for Metastatic Breast Cancer

Phase 2

Terminated

Conditions: Breast Cancer

Interventions: Drug: AZD6244
Drug: Dasatinib

First Posted Date: 2008-10-28

Last Posted Date: 2020-09-03

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 97

Registration Number: NCT00780676

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Clofarabine Plus Low-Dose Cytarabine Induction and Decitabine Consolidation in Frontline Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS)

Phase 2

Completed

Conditions: Acute Myeloid Leukemia
Myelodysplastic Syndrome

Interventions: Drug: Clofarabine
Drug: Cytarabine
Drug: Decitabine

First Posted Date: 2008-10-23

Last Posted Date: 2016-07-14

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 122

Registration Number: NCT00778375

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Lynne Cohen Consortium Project: Multi-Center Database/Registry

Completed

Conditions: Ovarian Cancer
Breast Cancer

Interventions: Other: Questionnaire

First Posted Date: 2008-10-22

Last Posted Date: 2014-07-31

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 176

Registration Number: NCT00776958

Locations: 🇺🇸
University of Alabama, Birmingham/Department of OB/GYN, Birmingham, Alabama, United States
🇺🇸
USC/Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

and more 1 locations

Measuring Non-Enhancing Glioblastoma Progression

Completed

Conditions: Brain Tumor
Glioblastoma

Interventions: Procedure: MRI/MRS Scan

First Posted Date: 2008-10-22

Last Posted Date: 2012-03-30

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 7

Registration Number: NCT00777686

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Longitudinal Study of Symptoms in Colorectal Cancer

Terminated

Conditions: Colorectal Cancer

Interventions: Behavioral: Questionnaires

First Posted Date: 2008-10-22

Last Posted Date: 2019-05-29

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 509

Registration Number: NCT00777192

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Radiation Therapy and Cardiac Enzymes

Completed

Conditions: Tumor

First Posted Date: 2008-10-22

Last Posted Date: 2018-01-10

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 30

Registration Number: NCT00777751

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Alemtuzumab + Rituximab Consolidation in CLL

Phase 2

Terminated

Conditions: Chronic Lymphocytic Leukemia
Leukemia

Interventions: Drug: Rituximab
Drug: Alemtuzumab

First Posted Date: 2008-10-13

Last Posted Date: 2015-06-23

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 1

Registration Number: NCT00771602

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Study of Temsirolimus, Topotecan, and Bortezomib

Phase 1

Completed

Conditions: Advanced Cancer

Interventions: Drug: Torisel (Temsirolimus)
Drug: Hycamtin (Topotecan)
Drug: Velcade (Bortezomib)

First Posted Date: 2008-10-10

Last Posted Date: 2013-02-13

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 80

Registration Number: NCT00770731

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

MK-0646 and Gemcitabine +/- Erlotinib for Patients With Advanced Pancreatic Cancer

Phase 1

Completed

Conditions: Pancreatic Cancer
Pancreatic Adenocarcinoma

Interventions: Drug: MK-0646
Drug: Gemcitabine
Drug: Erlotinib

First Posted Date: 2008-10-09

Last Posted Date: 2020-09-03

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 81

Registration Number: NCT00769483

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Preoperative Chemotherapy (Gemcitabine and Erlotinib) With or Without Radiation Therapy

Phase 2

Terminated

Conditions: Pancreatic Cancer

Interventions: Drug: Gemcitabine
Radiation: Radiation Therapy
Drug: Erlotinib
Procedure: Surgery

First Posted Date: 2008-10-06

Last Posted Date: 2016-05-19

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 5

Registration Number: NCT00766636

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy